Needham analyst Mike Cikos downgrades C3.ai (NYSE:AI) from Buy to Hold.
Oppenheimer Downgrades Fate Therapeutics to Perform
Oppenheimer analyst Matthew Biegler downgrades Fate Therapeutics (NASDAQ:FATE) from Outperform to Perform.
Needham Downgrades C3.ai to Hold
Needham analyst Mike Cikos downgrades C3.ai (NYSE:AI) from Buy to Hold.
Related Posts
Goodbye iPhone Battery Woes? This New iPhone 15 Feature Will Help The Battery Last Longer
Apple is finally heeding to all the iPhone battery complaints with a new feature in the just-launched iPhone 15 series.
Piper Sandler Maintains Overweight on Paylocity Holding, Raises Price Target to $297
Piper Sandler analyst Arvind Ramnani maintains Paylocity Holding (NASDAQ:PCTY) with a Overweight and raises the price target from $276 to $297.
Tesla Wants To Hire Prototype Vehicle Operators — But Is It For Low-Cost EV Or Robotaxi?
These operators will be part of the company's vehicle data collection team and will be responsible for improving the vehicles' self-driving performance by operating the prototypes in a designated area.